Matches in SemOpenAlex for { <https://semopenalex.org/work/W3107782112> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3107782112 abstract "Abstract Purpose: We report the treatment results of AVAgamma therapy combining gamma knife (GK) and bevacizumab for recurrent glioblastoma. Subjects: From August 2013 to April 2020, 44 patients (88 lesions) with recurrent glioblastoma treated with AVAgamma therapy as salvage therapy at the time of relapse after initial treatment. The average age is 61.5 years, with 26 men and 18 women. The tumor volume is 150 ml or less, and KPS is 40% or more as the indication of AVAgamma therapy. When the irradiation volume of GK is 15 ml or less, a single irradiation with a boundary dose of 20 to 26 Gy was performed, and when the irradiation volume was 15 ml or more, a single irradiation boundary dose was divided into two divided irradiations of 12 to 15 Gy. The mean therapeutic borderline dose was 24 Gy. Bevacizumab was administered 10 mg / kg or 15 mg / kg 1 to 10 times after GK. Methods: Median progression-free survival (mPFS), 6-month progression-free survival (PFS-6m), 6-month survival (OS-6m), median survival (mOS) from treatment with AVAgamma Considered mOS from initial treatment. Results: The mPFS from AVAgamma therapy was 5 months, PFS-6m was 37%, OS-6m was 79%, and mOS was 9 months. The mOS from initial treatment were 25 months. In relapsing glioma RPA classification, NABTT CNC class 5 mOS is 5.6 months, class 6 mOS is 6.4 months, but mOS from AVAgamma therapy is 9 months in class 5, 9 months in class 6. The survival time has been extended. Discussion: By AVAgamma therapy, it was thought that recurrent lesions were locally controlled and life prognosis was prolonged. Conclusion: AVAgamma therapy is thought to prolong the survival of recurrent glioblastoma and play an important role as salvage treatment." @default.
- W3107782112 created "2020-12-07" @default.
- W3107782112 creator A5005514301 @default.
- W3107782112 creator A5025735300 @default.
- W3107782112 creator A5034239395 @default.
- W3107782112 creator A5062466076 @default.
- W3107782112 creator A5065317007 @default.
- W3107782112 creator A5070213567 @default.
- W3107782112 creator A5083352307 @default.
- W3107782112 date "2020-11-01" @default.
- W3107782112 modified "2023-09-23" @default.
- W3107782112 title "RT-01 Treatment results of salvage gamma knife and bevacizumab (AVAgamma therapy) for recurrent glioblastoma" @default.
- W3107782112 doi "https://doi.org/10.1093/noajnl/vdaa143.046" @default.
- W3107782112 hasPublicationYear "2020" @default.
- W3107782112 type Work @default.
- W3107782112 sameAs 3107782112 @default.
- W3107782112 citedByCount "0" @default.
- W3107782112 crossrefType "journal-article" @default.
- W3107782112 hasAuthorship W3107782112A5005514301 @default.
- W3107782112 hasAuthorship W3107782112A5025735300 @default.
- W3107782112 hasAuthorship W3107782112A5034239395 @default.
- W3107782112 hasAuthorship W3107782112A5062466076 @default.
- W3107782112 hasAuthorship W3107782112A5065317007 @default.
- W3107782112 hasAuthorship W3107782112A5070213567 @default.
- W3107782112 hasAuthorship W3107782112A5083352307 @default.
- W3107782112 hasBestOaLocation W31077821121 @default.
- W3107782112 hasConcept C126322002 @default.
- W3107782112 hasConcept C126894567 @default.
- W3107782112 hasConcept C141071460 @default.
- W3107782112 hasConcept C143998085 @default.
- W3107782112 hasConcept C2776194525 @default.
- W3107782112 hasConcept C2776694085 @default.
- W3107782112 hasConcept C2777802072 @default.
- W3107782112 hasConcept C2780739268 @default.
- W3107782112 hasConcept C2780775027 @default.
- W3107782112 hasConcept C2989005 @default.
- W3107782112 hasConcept C3019894029 @default.
- W3107782112 hasConcept C502942594 @default.
- W3107782112 hasConcept C71924100 @default.
- W3107782112 hasConceptScore W3107782112C126322002 @default.
- W3107782112 hasConceptScore W3107782112C126894567 @default.
- W3107782112 hasConceptScore W3107782112C141071460 @default.
- W3107782112 hasConceptScore W3107782112C143998085 @default.
- W3107782112 hasConceptScore W3107782112C2776194525 @default.
- W3107782112 hasConceptScore W3107782112C2776694085 @default.
- W3107782112 hasConceptScore W3107782112C2777802072 @default.
- W3107782112 hasConceptScore W3107782112C2780739268 @default.
- W3107782112 hasConceptScore W3107782112C2780775027 @default.
- W3107782112 hasConceptScore W3107782112C2989005 @default.
- W3107782112 hasConceptScore W3107782112C3019894029 @default.
- W3107782112 hasConceptScore W3107782112C502942594 @default.
- W3107782112 hasConceptScore W3107782112C71924100 @default.
- W3107782112 hasLocation W31077821121 @default.
- W3107782112 hasLocation W31077821122 @default.
- W3107782112 hasOpenAccess W3107782112 @default.
- W3107782112 hasPrimaryLocation W31077821121 @default.
- W3107782112 hasRelatedWork W16708841 @default.
- W3107782112 hasRelatedWork W16896924 @default.
- W3107782112 hasRelatedWork W17235185 @default.
- W3107782112 hasRelatedWork W20302269 @default.
- W3107782112 hasRelatedWork W2871853 @default.
- W3107782112 hasRelatedWork W3819646 @default.
- W3107782112 hasRelatedWork W5346711 @default.
- W3107782112 hasRelatedWork W61283 @default.
- W3107782112 hasRelatedWork W7623919 @default.
- W3107782112 hasRelatedWork W21140677 @default.
- W3107782112 isParatext "false" @default.
- W3107782112 isRetracted "false" @default.
- W3107782112 magId "3107782112" @default.
- W3107782112 workType "article" @default.